Development of new treatment for juvenile myelomonocytic leukemia focusing on hematopoietic microenvironment

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K10105
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Pediatrics
• Research Institution: Shinshu University
• Principal Investigator: Sakashita Kazuo 信州大学, 医学部附属病院, 特任研究員 (10345746)
• Co-Investigator(Kenkyū-buntansha): 中沢 洋三 信州大学, 学術研究院医学系, 教授 (60397312)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: ＰＣＤＨ１７

Outline of Final Research Achievements

The aim is to clarify the hematopoietic microenvironmental molecules involved in the onset or progression of JMML, and to try to develop a novel molecular targeted therapeutic drug that is related to various clinical features. We reported that the adhesion molecule; protocadherin (PCDH) 17 gene is involved in the development of leukemia. We also found that PCDH17 acts as a tumor suppressor gene in hematopoietic tumors, and reported its potential as a target for novel molecular therapy

Free Research Field

小児血液

Academic Significance and Societal Importance of the Research Achievements

近年、腫瘍においては増殖シグナルや腫瘍特異的発現分子を標的とした治療薬の開発がはが盛んに行われている。今回の研究の成果は従来細胞間接着分子として働いていると考えられているPCDH17が細胞増殖に深く関与し、がん抑制遺伝子としての働きがあることをみいだした。このことはPCDH17が新規の分子標的治療薬としての可能性を示したことは学術的に大きな意義があると考えられる。